Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Jan

2010

Nabriva Therapeutics, AG: Series B $22M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Antiinfective, X - MRSA

Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Oct

2009

PrimeraDx, Inc.: Series C $20M

Posted in I - Series C, Q - 3Q09, R - NORTH EAST, X - Antiinfective, X - Device (Diagnostic), XX - MA

PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.

Oct

2009

Adamas Pharmaceuticals, Inc.: Series D $40M

Posted in I - Series D, Q - 3Q09, R - WEST, X - Antiinfective, X - CNS, X - Dementia, X - Influenza, X - Parkinson's, XX - CA

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Oct

2009

Union Springs Pharmaceuticals, Inc.: Series A $5M

Posted in I - Series A, Q - 3Q09, R - SOUTH EAST, X - Antiinfective, XX - KY

Union Springs Pharmaceuticals (Union, KY) a commercial-stage developer of OTC antiinfective washes for emergency first responders, closed a $5M Series A financing. Participants include Blue Chip Venture Company.

Sep

2009

Novacta Biosystems, Ltd.: Series B $21.6M

Posted in I - Series B, Q - 3Q09, R - INTERNATIONAL, X - Antibacterial, X - Antiinfective

Novacta Biosystems (United Kingdom) a pre-clinical stage biopharmaceutical company developing anti-invectives against C. difficile, closed a $21.6M Series B financing. Participants include Celtic Pharma.

Aug

2009

NanoBio Corp.: Series B $10M

Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - Antiinfective, X - Therapeutic Platform, X - Vaccines, XX - MA

NanoBio (Ann Arbor, MA) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $10M Series B financing, bringing the total round to $22M. Participants include Perseus.

Jun

2009

XORI Corp.: Series A $3M*

Posted in I - Series A, Q - 2Q09, R - NORTH WEST, X - Antibody, X - Antiinfective, X - Immunology, X - Oncology, XX - WA

XORI (Seattle, WA) a development-stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease, closed a $3M Series A financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.
*value was undisclosed

Mar

2009

Kenta Biotech, Ltd.: Series B $10M

Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - Antibacterial, X - Antibody, X - Antiinfective, X - Antiviral, X - Pneumonia

Kenta Biotech (Switzerland) clinical-stage developer of antibacterial and antiviral antibodies targeting Pseudomonas aeruginosa caused nosocomial pneumonia closed a $10M Series B financing. Participants in this round have not been identified.

Feb

2009

NanoBio Corp.: Series B $12M

Posted in I - Series B, Q - 1Q09, R - MID WEST, X - Antiinfective, X - Therapeutic Platform, X - Vaccines, XX - MI

NanoBio (Ann Arbor, MI) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $12M Series B financing. Participants include Perseus.

« Previous Entries

to top of page...